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THE PREVENTION AND TREATMENT OF ANAPLASMOSIS 
By James G. Miller 
Introduction 
Department of Pharmacology, University of Michigan, Ann Arbor, Mich. 
There have been a t  least 80 drugs proposed for the treatment of anaplas- 
mosis. The suggested efficacy of these agents has often been based on a small 
number of clinical cases, with an almost complete lack of prior information as 
to their specific activity, or lack of such activity, against Anaplasma marginale. 
The host specificity of the parasite has defeated many efforts to evolve a screen- 
ing method that would adapt itself to the examination of a large number of 
compounds. The previous lack of a preliminary screen has been a major stum- 
bling block in the rational chemotherapeutic approach to the problem. 
Methods of Study 
It is difficult to obtain clinical cases of anaplasmosis in ruminants other than 
the adult bovine, and attempts to grow even Anaplasma marginale in other 
hosts or in artificial media have not been successful. The role of the spleen in 
the host's response to anaplasmosis has long been recognized. An adult re- 
sistant carrier animal will undergo a relapse following splenectomy; and calves, 
which at  best exhibit only mild symptoms of the disease, become susceptible 
to acute anaplasmosis when splenectomized. This has lead to the use of sple- 
nectomized calves for the chemotherapeutic screening procedure. 
In the following experiments, male calves were splenectomized between 10 
and 14 days of age, and then inoculated with Anaplasma marginale 2 weeks 
later. The inoculum consisted of a subcutaneous injection of 5 cc. of citrated 
whole blood. A common carrier source was used throughout these experi- 
ments. This carrier was determined' to have the most virulent strain of Ana- 
plasma marginale available and, in fact, one of the most virulent that had ever 
been encountered. 
Various phases of the disease in splenectomized calves were examined by 
Lotze2 and also at  Louisiana State Uni~ersity,~ Baton Rouge, Louisiana, to 
determine their adaptability to a screening method. The incubation period 
varied widely even when, as in these experiments, a constant volume of inocu- 
lum,from a single source was used. 
It should be pointed out that the incubation period is usually not longer than 
60 days and that it can be entirely abolished by massive transfusions of highly 
infected blood. This wide variation in the incubation period makes it an unde- 
sirable criterion of drug activity. Similarly, the peak percentage of infested 
red blood cells cannot be utilized, as it varies widely from animal to animal. 
A peak infestation of 30 per cent of the red blood cells is likely to result in just 
as severe symptoms and anemia as in the instance of a red cell infestation reach- 
ing 85 per cent. A splenectomized calf that survives the initial attack of ana- 
plasmosis often undergoes a recurrent series of relapses of varying degrees of 
severity, so that this portion of the disease is not adaptable to the screening 
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* Range: 11  to 44 days. Mean: 22 days. Standard deviation: =t7  days. 
program. The only portion of the disease in splenectomized calves that is con- 
sistent enough to be used as a criterion for specific drug activity is the rate of 
infestation of red blood cells. The percentage of infested red blood cells doubles 
approximately every 24 hours until a peak is reached (FIGURE 1). For a com- 
pound to exhibit specific activity against the Anaplasma marginale, it would 
have to alter this pattern of cell infestation. 
Results 
The drugs previously used in the therapy of this disease can be classified as 
arsenicals, antimalarials, antimony derivatives, and dyes. Two antimalarials, 
chloroquine dihydrochloride4 and paludrine diphosphate16 were subjected to 
screening with splenectomized calves. In both instances, very high dosage 
levels failed to alter the course of red blood cell infestation (FIGURE 2) and were 
adjudged to be lacking specific activity against A naplasma marginale. 
Chlortetracy- 
cline was administered intravenously a t  the rate of 5 mg./lb. body weight a t  
various stages of erythrocyte infestation. In all instances there was no further 
increase in the level of infestation following treatment (FIGURE 3). Oxytetra- 
cycline gave similar results when administered intravenously a t  2.5 mg./lb. 
body weight. There was 100 per cent recovery in 32 animals treated with these 
antibiotics, as contrasted with 80 per cent fatalities in 24 untreated splenecto- 
mized calves! Chloramphenicol therapy resulted in a temporary inhibition of 
red blood cell infestation, which was confined to the period of treatment. Sub- 
sequent cell infestation often reached 80 to 90 per cent of all erythrocytes.6 
From these experiments, it was apparent that chlortetracycline and oxytetra- 
cycline had a demonstrable effect on A naplasma marginale. Further experi- 
ments were conducted to outline the parameters of this action, and its possible 
utility, if any, in the treatment of this disease. Subinoculations from chlor- 
tetracycline- and oxytetracycline-treated calves indicated that they were still 
carriers of virulent A naplasma margin~le.~ Several attempts were made to 
Chlortetracycline and oxytetracycline were also screened. 
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D A Y S  F R O M  1 %  I N F E C T I O N  
FIGURE 1. A graph to show the rapid increase of the ercentage of infected red blood cells in four 
untreated splenectomized calves inoculated with 5 C C .  of who?e blood from the common carrier. The ac- 
tivity of chemotherapeutic agents against the AnaPlasnm marginale is evaluated by their ability t o  halt 








DAYS AFTER I N O C U L A T I O N  
-- untreated control : - - - - trelrttid calf. 
FIGURE 2. The results of continuous treatment with chloroquine dihydrochloride during the, patent 
phase of ana lasmosis in a splenectomized calf. The dosage was 5.8 mg./lb. daily, administered lntrave- 
nously in a 8vided dose four hours apart (from Miller el a2.9. 
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DAYS AFTER INOCULATION 
FIGURE 3. A gra h to  show the result of a single dose of chlortetracycline on the increase of infected 
red cells. The s o d l i n e  indicates the percentage of infected red cells in the treated calf. The broken 
portion of that line indicates the day on which chlortetracycline was given. The dotted line indicates the 
percentage of infected red cells of the untreated control calf (from Miller el al.8).  
sterilize carriers of anaplasmosis using large doses of chlortetracycline over a 
short period of time. These experiments failed to rid carriers of the infection,' 
in spite of the fact that the blood of these animals was free of infective Ana- 
plasma marginale for a brief period following therapy? Similar results were 
obtained when chlortetracycline and oxytetracycline were administered a t  the 
rates of 5 and 2.5 mg./lb. body weight, intravenously, for periods of 16 and 20 
days respectivelyP Subsequent experiments with both antibiotics, at  increased 
dosage levels over a period of 20 days,1° resulted in sterilization of the blood of 
carrier animals for a t  least 100 days and up to 360 days, a t  the last determina- 
tion. This was accompanied by the disappearance of A naplasma marginale 
complement-fixing antibodies at  an early date following therapy. 
Cer- 
tainly, if pretreatment could prevent or ameliorate an epizootic, a very real ad- 
vance would have been made. It soon became apparent, however, that admin- 
The possible prophylactic application of these antibiotics was explored. 
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istration of chlortetracycline early in the prepatent phase of the disease served 
only to delay the onset of clinical symptomss far beyond the usual incubation 
period, without any advantageous effect on the acute phase. Treatment with 
chlortetracycline and oxytetracycline early in the patent phase of the disease, 
that is, between 1 and 10 per cent of infested erythrocytes, resulted in no further 
increase in red blood cell infestation, amelioration of clinical symptoms, and no 
subsequent relapses up to 120 days following the rap^.^ Animals treated in 
this manner, however, of ten developed an undesirable degree of anemia. 
In  1952, a survey of clinical cases of anaplasmosis was conducted in Louisi- 
ana.” One hundred and thirty-two cases of the disease were available for study. 
Blood samples were collected a t  the time of treatment, and red and white blood 
cell counts, red blood cell volume, hemoglobin content, and degree of erythro- 
cyte infestation were determined. Sixty of these animals were treated with 
chlortetracycline and 52 with oxytetracycline. Twenty animals received the 
treatment that was currently employed by the attending veterinarian. These 
treatments were classified as ‘nonspecific,’ as they were supportive in nature; 
medication involved calcium gluconate, sodium caccodylate, and strychnine 
sulfate. 
Discussion 
An initial screening procedure is fundamental in the chemotherapeutic ap- 
proach to anaplasmosis. Although the multiplicity of suggested treatments is 
regrettable, it is understandable in view of the lack of a satisfactory preliminary 
screen for specific activity. The use of the splenectomized calf makes available 
an experimental tool for the study of anaplasmacidal or Anaplasma inhibitory 
activity, but this is not an entirely satisfactory approach. The chief disadvan- 
tages of this method are the expense and time involved. It is therefore en- 
tirely unsuited to the mass screening approach, where hundreds of chemical 
structures are to be tested, but it is applicable to careful and considered experi- 
mentation with a few drugs. In the author’s opinion, there is little doubt that 
the results obtained by this method are valid. In no instance has an apparent 
specific activity of a drug in the splenectomized calf failed to be substantiated in 
the adult nonsplenectomized animal, nor has the lack of activity in the experi- 
mental animal been confronted by activity in the adult. 
The specific activity of a drug against Anaplasma marginale in the splenecto- 
mized calf does not mean that the particular agent will be of value in the therapy 
of the disease. This in itself is a problem that must be answered in the clinical 
environment. The interpretations of such clinical studies, if properly planned, 
will be greatly aided by the information obtained from the screening program. 
Certainly the mere recovery of a certain percentage of a group of treated animals 
is an inadequate criterion in the therapy of many diseases, including anaplas- 
mosis. 
One of the most striking features observed in the clinical trials in Louisiana 
was the late stage of the disease a t  which the animals were presented for treat- 
ment. Often the animal was afebrile, jaundiced, anemic, with a low level of 
erythrocytes infected. Seventy-two per cent of all animals in the field trial 
had less than 4 gm. of hemoglobin per 100 cc. of blood; this may be compared 
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with a similar survey in Oklahoma'? in which only 14 per cent of the animals 
had less than this amount of hemoglobin. These differences, explainable per- 
haps on the basis of a less virulent form of anaplasmosis, or because of the epi- 
zootic rather than the sporadic proportions of the disease in Oklahoma, serve to 
illustrate the varying conditions under which anaplasmosis is treated. It is 
doubtful that anaplasmosis can be effectively treated in the postfebrile, acutely 
anemic period with a specific chemotherapeutic agent. The rapid red cell in- 
festation, which could have been halted by chlortetracycline or oxytetracycline, 
has already taken place. The phase of the disease that should be given immedi- 
ate attention is the acute anemia. Treatment may logically embody repeated 
transfusions of whole blood, hematopoietic stimulating therapy, and nursing 
care. 
At this time, protection of susceptible animals against anaplasmosis is not a 
practical procedure in this country. Young animals inoculated with Ana- 
plasma marginale become resistant to further infection, but remain carriers of 
the disease. This carrier status discourages the widespread inoculation of 
young animals, particularly in view of the susceptible cattle population in many 
areas. 
Chlortetracycline and oxytetracycline have been used prophylactically to 
avert the crippling economic losses associated with an epizootic of anaplasmosis. 
This prophylactic use is based on the treatment of animals in the early patent 
phase of the disease, when Anaplasma marginale are present in less than 10 per 
cent of the erythrocytes. The examination of blood smears every five days 
proved to be a suitable basis for the initiation of therapy. This approach is 
naturally limited to those instances where an epizootic is imminent in a small 
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